Introduction
Nitric oxide is a widespread signaling molecule that participates in virtually every cellular and organ function in the body (for an historic perspective see [1] ). The purpose of this review is to highlight recent studies relating nitric oxide production in health and disease to clinical nutrition and metabolism. We provide the latest insight in the mechanisms that regulate nitric oxide production under various conditions and the potential options for nutrition-based therapy. Outside the scope of the review are the factors that influence bioavailability of nitric oxide by scavenging or inactivation via hemoglobin, superoxide or oxidation [2] .
Nitric oxide production
Nitric oxide is a highly reactive molecule, which complicates its direct measurements. Moreover, nitric oxide is produced at various locations in the body. Furthermore, nitric oxide production involves different enzyme isoforms and nonenzymatic pathways. All this adds to the various roles of nitric oxide in (patho)physiology as will be outlined below.
Nitric oxide metabolism and nitric oxide synthase isoforms
Endogenous nitric oxide is derived largely from enzymatic pathways, but a nonenzymatic pathway also exists ( Fig. 1) . Enzymatic nitric oxide formation is catalyzed by nitric oxide synthase (NOS) through a series of redox reactions, with degradation of L-arginine to L-citrulline and nitric oxide, and in the presence of oxygen and NADPH [3, 4] . Three isoforms of NOS are recognized: endothelial NOS (eNOS or NOS3), neuronal NOS (nNOS or NOS1) and inducible NOS (iNOS or NOS2). NOS1 and NOS3 are constitutive enzymes that are controlled by intracellular Ca 2þ /calmodulin; NOS2 is inducible at the level of gene transcription, Ca 2þ independent and expressed by macrophages and other tissues in response to (pro)inflammatory mediators. A mitochondrial NOS (mtNOS) isoform is still under debate. Tetrahydrobiopterin (BH4) is an essential cofactor for NOS; BH4 is synthesized from guanosine-5'-triphosphate (GTP) via the GTP-cyclohydrolase-I (GTP-CH) pathway. Other cofactors are flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) and heme (for recent reviews see [5, 6] ).
The nonenzymatic production of nitric oxide involves production of nitric oxide from nitrite via multiple pathways, particularly under acidic conditions (e.g. following ischemia) [7] and occurs mainly in tissue [8] . The main pathway is via nitrite reduction:
Under ischemic conditions with acidosis, nitrite-mediated nitric oxide production approaches that of maximum constitutive NOS (cNOS) production, making this route an alternative under ischemic conditions in which nitric oxide production from NOS is impaired [8] .
Role of nitric oxide in physiology and pathophysiology
Nitric oxide is a key molecule involved in a variety of biological functions throughout the whole body [4] . In the vasculature, nitric oxide (major part from NOS3, but NOS1 is present around arterioles) regulates vascular tone and blood flow by activating soluble guanylate cyclase (sGC) in the vascular smooth muscle.
Moreover, it is essential for leukocyte adhesion and platelet aggregation, and it controls mitochondrial oxygen consumption by inhibiting cytochrome c oxidase. Abnormalities in vascular nitric oxide production and transport result in endothelial dysfunction with various cardiovascular disorders such as hypertension, atherosclerosis and angiogenesis-associated disorders (for a recent review see [5] ). Interestingly, NOS3 can generate superoxide when the concentrations of either L-arginine or BH4 are low. This 'uncoupling' of NOS3 occurs in several disorders such as diabetes, hypercholesterolemia and hypertension [9] . Nitric oxide production was also suggested as a major inherited factor of insulin sensitivity, with diet-induced oxidative scavenging of nitric oxide as a first hit towards insulin resistance [10] . Recently, a higher nitric oxide production in pregnant Indian women with a low BMI was reported [11] . Nitric oxide in the brain regulates many physiological processes affecting behavior and cognitive function including synaptic plasticity. In addition, it also controls brain blood flow, promotes angiogenesis, maintains cellular redox state, cell immunity and neuronal survival. Its overproduction may lead to neurodegeneration [12] . Nitric oxide from NOS2 was originally identified in macrophages and contributes to the cytotoxic actions of these cells. Nitric oxide produced by NOS2 in the vasculature is involved in the profound vasodilatation of septic shock [4] . Moreover, as a result of oxidative stress, cellular respiration is inhibited and tissues become unable to utilize available oxygen, called metabolic hypoxia. This might not be exclusive to septic shock but could also contribute to other inflammatory and degenerative conditions [13] . Nitric oxide generated by NOS2 promotes atherosclerosis either directly or via the formation of nitric oxide adducts such as peroxynitrite [1] .
Measurement of nitric oxide production
The half-life of nitric oxide in blood is very short (<1 s) due to rapid oxidation by oxyhemoglobin to nitrate and nitrite (cumulatively indicated as NOx), binding of nitric oxide to several cell structures or nitric oxide scavenging. Therefore, nitric oxide in vivo is often measured as the concentration of its metabolites (NOx), as a surrogate indicator of nitric oxide production. NOx can be measured in plasma or within cells (e.g. polymorphonuclear neutrophils [14] ) or even in saliva, where it is partly derived from bacterial nitric oxide production in the oral cavity [15] . NOx analysis is widely available and relatively easy, but can be biased by dietary nitrate intake, renal clearance rate or (gut) bacterial production. For a recent review on nitrite/nitrate analysis, see [16] . Measurement of nitric oxide in exhaled air is also relatively easy and used as a marker for pulmonary inflammation. However, the shape of the exhaled nitric oxide profile is affected by a variability in ventilation and nitric oxide production, as seen in asthmatic patients following an exercise challenge, which may impact the physiological interpretation [17] .
A more sophisticated and more direct method is the measurement of nitric oxide production as the conversion of intravenous or orally administered stable isotope-
-guanidino-arginine) to labeled nitric oxide metabolites ( 15 NOx). 15 NOx can be measured in urine by sampling over a certain time period with correction for creatinine excretion after bolus tracer infusion [10,18 ,19] ; alternatively, fractional or absolute synthetic rate can be measured in plasma/whole blood during steady-state arginine tracer infusion [20, 21] . Another approach is measurement of the conversion of labeled arginine to
N]-citrulline), which is produced concomitantly with nitric oxide.
]-citrulline) and arterial blood sampling enables the calculation of the absolute rate of whole body nitric oxide production. The latter method was first introduced by Castillo et al. [22] and has since been used by several groups under various conditions, including recent studies in neonates [23] , patients with sepsis [24 ,25 ] and mice [26, 27] . Analytical aspects involve the combination of gas or liquid chromatography and mass spectrometry to measure isotopic enrichments [28] .
Discrepancies between nitric oxide production as measured by NOx and stable isotopes, however, exist and question the validity of the techniques. An increase in NOx with no concomitant increase in (stable isotope measured) nitric oxide production [24 ,25 ] may be due to altered renal function, extracellular volume changes or delayed conversion of nitric oxide to nitrate. On the contrary, nitric oxide production as measured by stable isotopes may not account for possible intracellular/organ compartmentalization and, therefore, underestimate nitric oxide production [29] . The direct conversion of citrulline to arginine and subsequently to nitric oxide (citrulline-nitric oxide cycle) in macrophages [30] or endothelial cells [31] , as well as urea metabolism or compartmentalized nitric oxide production from proteinderived arginine [27] are examples of compartmentalization. Therefore, the measured nitric oxide production probably represents minimal nitric oxide production. Nitric oxide production rate measured with stable isotopes also varies: between 0.15 and 2.2 mmol/kg h in healthy individuals, between 0.14 and 0.25 mmol/kg h in pregnant Indian women and between 0.20 and 0.80 mmol/kg h in patients with sepsis (reviewed in [29] ) [11,24 ,25 ] . Differences in isotopes, equations and analytical techniques may underlie this variation, but make it difficult to compare absolute values of nitric oxide production between studies.
In tissue samples or in cells, total amounts of NOS proteins (from different isoforms) or NOS activities have been measured as indicators of tissue-specific nitric oxide production [32] . Moreover, activity of GTP-CH and concentrations of BH4 and NADPH play a role in modulating NOS activity and as such facilitate nitric oxide production [32] . The specificity of NOS1 or NOS3 activation can be indicated by the specific site of enzyme (de)phosphorylation [32] . Differences between animal species also exist such as for LPS-induced nitric oxide production by macrophages [33] .
Regulation of nitric oxide production in health
Nitric oxide production is dependent on the availability of its precursor arginine and activity of the various NOS enzymes. Activity of the various NOS enzymes can also be affected by factors that influence the concentration of NOS proteins and cofactors (including BH4, NADPH and Ca 2þ ) or alter NOS expression and kinetic properties. Related to the nonenzymatic nitrite-nitric oxide pathway, pH, oxygen tension, nitrite and reducing substrate concentration affect nitric oxide generation [8] . Dietary factors that regulate nitric oxide production are described below and summarized in Table 1 [9, 26, [34] [35] [36] [37] [38] [39] [40] 41 ,42].
Dietary factors that regulate nitric oxide production
Dietary factors that regulate nitric oxide production include substrate (arginine) availability and others that affect NOS activity (see Fig. 1 ).
Substrate (arginine) availability
At normal concentrations of arginine, NOS3 should be saturated. However, increased NOS3 activity occurs with arginine supplementation, known as the arginine paradox, due to enhanced L-arginine-induced BH4 production with promotion of nitric oxide production by NOS3 [37] . Plasma arginine availability can thus affect nitric oxide production, confirmed by the positive correlation shown in mice models [26] . Arginine availability is influenced by its dietary intake and endogenous production (protein breakdown and de-novo synthesis from citrulline), as well as by arginine clearance (by arginase and protein synthesis) [3] . Arginase reciprocally regulates nitric oxide levels in endothelial cells by competing with NOS for the substrate L-arginine [43] . The intracellular transport of arginine by the cationic amino acid transporter and the competition with lysine also determines its availability as a precursor for nitric oxide [39] . In studies in mice that express only 5-10% of ornithine transcarbamylase (OTC) activity, resulting in impaired citrulline availability and de-novo arginine production, nitric oxide production was reduced; supplementation of citrulline or urea cycle intermediates was proposed to sustain nitric oxide production [26, 27] . The close coupling between citrulline with de-novo arginine synthesis pathway on the one hand and nitric oxide production on the other hand is also indicated by the colocalization in endothelial cells of NOS3 with the enzymes argininosuccinate synthase (ASS) and argininsuccinate lyase (ASL) [31] . The authors, therefore, proposed that both ASS and ASL could be therapeutic targets for modulating endothelial nitric oxide production [31] . The interorgan exchange of ornithine might play a crucial role to support citrulline production by the small intestine [27] . Direct postprandial utilization of meal arginine for nitric oxide production was considered to be low [19] .
Other dietary factors that affect nitric oxide synthase activity
Wu and Meininger [35] and Li et al. [34] extensively reviewed regulation of nitric oxide production by single dietary factors. These dietary factors are either beneficial to health or contribute to the pathogenesis of chronic diseases, partially through modulation of nitric oxide production by iNOS or cNOS [35] . A high-fat (palmitate) diet with high levels of free fatty acids resulted in lower arterial NOS3 phosphorylation, hypertension and vascular dysfunction as a result of free fatty acid-mediated impairment of NOS3 phosphorylation and nitric oxide production [41 ] . Dietary docosahexaenoic acid supplementation in neonatal piglets increased NOS activity and cofactors for NOS in brain, liver and muscle, whereas dietary cholesterol only increased NOS activity in the brain [32] .
Related to complex dietary factors, a meal challenge with high sucrose and high fat in rats decreased whole body nitric oxide production and nitric oxide-mediated vascular response, strongly related to plasma triglyceride levels [18 ] . Diet-induced insulin release stimulates nitric oxide production in endothelial cells by increasing the production of NADPH and BH4 in endothelial cells, which may modulate tissue blood flow [37] . This insulin effect may be the result of a larger fraction of arginine flux converted to NOx, as arginine flux is even reduced during acute hyperinsulinemia [21] .
Regulation of nitric oxide production in disease
Diseases can be characterized either by lack or excess of nitric oxide, as described above under pathophysiology. Protection against a decrease in constitutive nitric oxide production in the vasculature may prevent the development of vascular disease, whereas inhibition of excessive inducible nitric oxide production could also be a therapeutic target. Latest insights in nitric oxide production in diseases and underlying mechanism that offer therapeutic options are outlined below and also summarized in Table 1 .
Mechanisms affecting nitric oxide production in disease
Nitric oxide production is affected in sepsis and trauma, undernutrition and vascular disease and other diseases.
Sepsis and trauma
Nitric oxide production, as measured by the conversion of stable isotope-labeled arginine to citrulline, was equal or even lowered in patients with sepsis [24 ,25 ] . Despite the increased protein breakdown, arginine flux was similar but plasma arginine was lower. This seems attributed to increased plasma arginine clearance [24 ] and inadequate de-novo arginine production secondary to reduced citrulline production [25 ] . It was, therefore, suggested that increasing arginine availability by arginine or citrulline supplementation might restore the arginine balance and nitric oxide production [24 ,25 ] .
In an in-vitro model of macrophages, arginine availability was a limiting factor for nitric oxide production, measured as nitrite concentration. However, citrulline was a potential substitute to restore nitric oxide production in the arginine-deprived environment, whereas glutamine interfered with citrulline-mediated nitric oxide production [38] . Lysine Inhibition of nitric oxide production by reducing intracellular arginine transport (especially at relatively low plasma arginine) in various cell types [34, 35, 39] Glycine Binds to NMDA receptor resulting in Ca 2þ influx and NOS1 activation for nitric oxide production; reduces NOS2 activity Attenuates hepatic injury under inflammatory conditions [34, 35] Taurine Stimulates nitric oxide production by cNOS; inhibits NOS2 expression and subsequent nitric oxide production in various cell types Suggested to protect the host against oxidant-induced tissue damage [34, 35] Homocysteine/ methionine Dose-dependent decrease in nitric oxide production, which seems due to elevated ADMA; promotes NOS2 expression in vascular smooth muscle cells Impaired endothelium-dependent relaxation with high homocysteine; increased NOS2-induced oxidative stress may be responsible for atherosclerosis in obese and diabetics [34, 35, 40] Carbohydrates Glucose Nitric oxide production is dependent of glucose (as source of NADPH), but hyperglycemia inhibits nitric oxide production by NOS3 in large vessels (by activating the glucosamine synthetic pathway), whereas stimulates nitric oxide in capillaries; inhibition of NOS2-mediated nitric oxide production Hyperglycemia has a role in the development and progression of endothelial dysfunction in diabetes and induction of insulin insensitivity; role in pathogenesis of retinal degradation, b-cell dysfunction and nephropathy in diabetes [35, 37] The authors, therefore, suggested that, in conditions of arginine deficiency (such as trauma or after surgery), citrulline supplementation might be a powerful way to restore nitric oxide production. Glutamine administration could be a mechanism to control excessive nitric oxide production by macrophages (authors proposed sepsis) [38] . In a mice model with reduced OTC activity (and thus citrulline production), treatment with LPS-stimulated [35, 41 ] Unsaturated fatty acids: n-3 (fish oil, EPA and DHA), n-6 (linoleic acid), n-9 (oleic acid)
n-3 and n-6 PUFA increase nitric oxide production by endothelial cells, n-9 PUFA inhibit nitric oxide production by decreasing NOS3 activity; proportion of cellular n-3 and n-6 fatty acids concentration is a major determinant for nitric oxide production by NOS2
PUFAs regulate vascular endothelial function partially through alterations in nitric oxide production; fish oil, DHA and EPA considered beneficial for cardiovascular function; increasing plasma concentrations of n-9 fatty acid may contribute to the pathogenesis of endothelial dysfunction; involved in inflammatory response [35] Vitamins Vitamin C, A, E, folic acid; vitamin K and carotenoids Enhanced NOS3-mediated nitric oxide production and endotheliumdependent relaxation
Cardioprotective effects [35] ADMA, N G -methyl-L-arginine; BH4, tetrahydrobiopterin; cNOS, constitutive NOS (NOS1 and NOS3); DHA, docosahexaenoic acid (C22:6 n-3); EPA, eicopentaenoic acid (C20:5 n-3); NOS, nitric oxide synthase; PUFA, polyunsaturated fatty acid; ROS, reactive oxygen species. protein breakdown with maintenance of nitric oxide production [26] .
Plasma levels of the endogenous NOS inhibitor N Gmethyl-L-arginine (ADMA) showed a wider range in patients with sepsis as compared with healthy controls, but were not related to nitric oxide production, protein breakdown or renal and liver function [24 ] . On the contrary, however, higher ADMA levels were related to higher mortality in sepsis [24 ,44] .
Undernutrition in children and neonates
In children with edematous severe undernutrition, nitric oxide production (as measured by urinary 15 NOx after labeled arginine infusion) was not different from the recovery state, whereas both plasma arginine and arginine flux were lowered [20] . An arginine-deficient diet in neonatal pigs reduced nitric oxide production, which suggests that arginine availability, probably largely controlled by the splanchnic area, drives nitric oxide production [23] .
Vascular disease
Arginase has been proposed as an attractive therapy in modifying the arterial response to injury and may offer therapeutic interventions in the treatment of vascular disease (for review see [45] ). However, a moderate increase in arginase I plasma level did not affect plasma arginine and major changes in arginase levels are probably needed to induce potential clinically relevant effects [46] . Pharmacological inhibition of arginase activity with N v -hydroxy-nor-L-arginine in a rat model of spontaneous hypertension increased nitric oxide production (NOx) with reduced blood pressure and improved reactivity of resistance vessels [47] . However, the effect was not completely nitric oxide mediated, as NOS inhibition did not fully abolish the effect of the arginase inhibitor. The authors proposed selective arginase inhibition as a potential new therapeutic strategy against hypertension [47] . Moreover, L-arginine was proposed as therapy in hypertension to interrupt the vicious cycle that initiates and maintains low nitric oxide [36] .
Of the various cardiovascular risk factors studied, homocysteine levels show a strong inverse relation with nitric oxide production, as measured by the urinary [
15 N]-nitrate excretion derived from labeled arginine [40] , specifically by NOS3 [35] . Decreased nitric oxide production resulting from a deficiency in BH4 contributes to the impaired action of insulin in the vasculature of obese and diabetic individuals [37] .
Conclusion
Implications of disturbed nitric oxide production in diseases are various and depend on whether lack or excess of nitric oxide production occurs. Dietary factors potentially can modulate nitric oxide production. Substrate bioavailability is crucial, but citrulline supplementation may be a good alternative as arginine precursor. Future research that extends our understanding of the regulation and adequate measurement of nitric oxide production at the organ level and by the different NOS isoforms is needed to align with adequate therapy. Moreover, the interrelation between arginine, citrulline and glutamine in the regulation of nitric oxide production, as well as the interaction and possible synergy between various dietary factors that affect nitric oxide production need further study.
